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ABSTRACT
As the biomanufacturing (BioMAN) initiative within the MIT Center for Biomedical Innovation
enters its third year of active research, the competitive landscape and sources of resources to
support biomanufacturing research have rapidly changed. This research is an attempt to
provide insight into the following primary questions:
o What research strategies could BioMAN effectively employ moving forward?
o What is a specific example of BioMAN research targeted towards new potential
resource sources?
o What are the details of the research approach for a project that would be of interest to
both existing and new resource sources?
By leveraging a competitive analysis framework, a recommendation was developed for BioMAN
to pursue the market segment of system-based research-centric programs without offering
training or custom projects. Specific potential resource sources and collaboration partners
were identified towards meeting this target market.
An example interdisciplinary research program proposal was constructed with the intent to
submit to the Alfred P. Sloan Foundation. Additionally, the details of planned approach to a
project focused on biomanufacture location decisions were developed towards attracting
support from both industrial partners and non-profit foundations.
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Title: Professor of Statistics and Management Sciences, MIT Sloan School of Management
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1 Research Motivation and Intent
1.1 M.I.T. Center for Biomedical Innovation Biomanufacturing Research
Initiative
One of the research areas being pursued by the Center for Biomedical Innovation (CBI) is that of
biomanufacturing research (with the specific MIT CBI biomanufacturing initiative referred to as
"BioMAN"). BioMAN research currently intends to be focused in two areas:(1)
* Evaluation of scenarios of biomanufacturing futures
o Influence of associated technology, policy, and business dynamics
* New tool and technologies specific to biomanufacturing
Enabling these focus areas is a community of subject matter experts from academia, industry,
and government brought together in a safe-haven environment to plan and perform the
research deemed to be valuable.(2)
1.2 Research Intent
As BioMAN enters its third year of active research, the competitive landscape and sources of
resources to support biomanufacturing research have been rapidly changing. It is the intent of
this research to answer the following questions:
What research strategies could BioMAN effectively employ moving forward?
o Leveraging a competitive analysis framework, what does a combination of
examination of existing consortia and qualitative primary data specific to
BioMAN mean in practice?
o Are there actionable recommendations that can be provided to BioMAN based
on the performed analysis?
* Identification of and rationale for potential resource source(s)
* Identification of and rationale for potential collaboration partners
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* Can a specific example of an actionable recommendation around new potential
resource source(s) be formed that would further BioMAN and be of interest to the
community of subject matter experts?
* What are the details of the research approach for a project that would be of interest to
existing resource source(s), specifically one or more industrial partners, and new
potential resource source(s)?
The three main chapters of this thesis aim to address the three primary questions in the list
above in an interconnected manner.
In an attempt to create value-adding answers to the final two questions above, the specific
example towards a new potential resource source, that has been developed in collaboration
with a number of potential principal investigators at MIT and elsewhere, is a proposal to the
Alfred P. Sloan Foundation of New York in the area of "Ensuring Safety, Integrity, and Value
Optimization in the Global Biopharmaceutical Supply Chain." The details of research approach
for a project of interest for industrial partners has been done for a project in the area of
"Biomanufacture Location Decisions in the Prospect of Regional Volatility."
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2 BioMAN Research Strategy Options
In analyzing the research strategy options for BioMAN, a conceptual framework for determining
target market segment(s) is introduced and then detailed with research and examples from
three sources:
1. Published academic research on rationale for having and joining consortia
2. Existing consortia and their publicly available information
3. Interviews with Stacy Springs, Ph.D., director of BioMAN
With the determined target market segment(s), specifics of marketing and potential resource
source(s) are investigated.
2.1 Conceptual Framework
The determination of a research strategy within the context of an academic consortium has at
least two defining dimensions:
* Expected timeframe for return on investment from consortium research
o For simplicity and application to BioMAN, possible timeframes are described as
near-term (e.g. in the next year, shorter than a Ph.D. thesis) and longer-term
* Extent to which existing academic researchers (and their associated strengths and
interests) will be utilized compared to building a custom organization
Each of these dimensions is on a continuum and each may change over time for a given
academic consortium and/or differ across research projects. However, some governing
description of intent along these two dimensions helps determine the relevant potential
market(s) and marketplace analysis techniques.
2.1.1 Example of Balancing Timeframies for Consortium Research
In some relevant research consortium situations, the balance of near-term and longer-term
value has been explicitly separated. This appears to be particularly well demonstrated by the
Dundee Kinase Consortium within the Division of Signal Transduction Therapy in the School of
Life Sciences at the University of Dundee, where the University provides both general
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consortium research (accounting for approximately two-thirds of the total funds) in the area of
dissecting signal transduction pathways to identify novel drug targets and provides custom
project services for additional fees (one-third of the total funds). In order to have access to
custom project services with the Dundee Kinase experts, the sponsor partner must be fully
invested in the consortium. Leveraging this dual opportunity, or bundled research consortium
solution, the Dundee Kinase Consortium has been able to retain consortium membership from
Pfizer, GlaxoSmithKline, and AstraZeneca amongst others committed for fourteen years and in
excess of thirty-four million pounds (approximately fifty million US dollars) and secured fifty
research positions.(3; 4)
In its intended two prong research program of analytical tools (near-term) and
biomanufacturing futures (longer-term), BioMAN is planning to utilize a similar balancing of
timeframes for return on investment from the consortium research. The BioMAN situation is
complicated by the possibility of one or more potential consortium member(s) electing to
pursue near-term or custom project services directly with one or more of the relevant
researchers and not electing to participate in the bundled offering of both near-term and
longer-term. While likely to enhance short-term research value for the enterprising consortium
member(s) and faculty, such custom projects would detract value to other consortium
members and from the longer-term research objectives. In some ways, the strong potential for
transformation from a consortium to a custom project was recently demonstrated by a MIT
affiliated consortium, Consortium for the Advancement of Manufacturing in Pharmacy (CAMP),
which had eight member companies in addition to MIT and Purdue as recently as 2005.(5)
Amongst the CAMP research projects were those aimed at designing continuous manufacturing
of pharmaceutical products. By September of 2007, Novartis (one of the CAMP members
companies) had come to terms with MIT on a ten-year dedicated, custom continuous
manufacturing project(6) and CAMP is no longer an active consortium. (5)
2.1.2 Impact of Leveraging Existing Organizational Strengths and Interests
The extent to which existing researchers are to be utilized in the research strategy is dependent
upon the relevant expertise of those researchers and the availability of new resources and/or
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collaborations to enable a modification of strengths and interests. Of additional consideration
regarding the extent of leveraging existing organizational strengths and interests is whether the
creation of the research consortium is initiated by the organization expected to conduct the
research ("an engineered process") or whether the consortium is created by the resource
source(s), which select the relevant consortium partners ("an emergent process").(7) BioMAN
is an example of the former origin, where the organizational strengths and interests of principal
investigators within the MIT community relevant to biomanufacturing attracted resources to
their current and/or potential research. The International Serious Adverse Event Consortium is
an example of the latter origin, where a US Food and Drug Administration (FDA) Industrial
Advisory Board recommended an "independent industrial biomedical consortium" be formed
to bring industry and regulators together to build a better understanding of the biology of drug
induced serious events.(7) Representative resulting consortium research strategy roadmaps
are presented in Figure 1 for the two extremes of leveraging existing organizational strengths
and interests.
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Figure 1. Representative Roadmaps of Consortium Research Strategy for A. Consortium
Intending to Primarily Leveraging Existing Organizational Strengths and Interests
("Engineered"); and B. Consortium Originating with Validated Opportunities ("Emergent")
The most notable difference in logic between the two roadmaps depicted in Figure 1 is the
inclusion of a reactive feedback loop in the roadmap in Figure 1A as the organization needs to
take the extra step of validating its offering in the marketplace, as opposed to the roadmap in
Figure 1B where the marketplace (in the form of one or more resource sources) has requested
or validated the product in advance of developing the organizational capabilities. Each of the
two roadmaps has advantages and challenges associated with it: at a summary level, a
consortium leveraging existing potential (Figure 1A) can come up to speed quickly but may not
gain significant market traction and the opposites apply to the original validated consortium
(Figure 1B).(8) Independent of the origin of the consortium and its associated resources, the
underlying marketplace and analytical techniques to investigate that market are consistent.
2.1.3 Analytical Techniques to Investigate the Marketplace of BioMAN
Towards understanding which market segment(s) and/or opportunities BioMAN could
effectively target, a marketplace analysis specific to BioMAN under the framework depicted in
Figure 2 which is derived from multiple publications on marketing and opportunity
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evaluation.(9; 10; 11) This analysis framework attempts to provide insight into the available
opportunities and the positioning of BioMAN capabilities relative to those opportunities. Each
of the three primary aspects of the framework will be discussed in the subsequent sections.
* Competitor Attributes
* Customer Rationale
* Existing Capabilities
* Collaborations
* Targeted Segments
* Product Positioning
Figure 2. Contents of the BioMAN Marketplace Analysis
2.2 Market and Attributes
In advance of detailing the competitors and customers for BioMAN, it will be helpful to define
the market that encompasses BioMAN. (9; 11) The BioMAN research objective is defined
broadly(1) and the potential market will be defined as "interdisciplinary research in technology,
policy, and business relevant to biomanufacturing." This broad definition allows for
consideration of a number of competitors and customers, which will allow for a rich attribute
space and large number of market segments.
One way to simultaneously view the market and the context of participants in the market is
with the five forces of market structural attractiveness as first suggested by Michael Porter.(10)
This framework groups the market into current rivals within the market, potential entrants,
suppliers, buyers, and substitutes. This framework with general groups of each of the five types
specific to BioMAN is presented in Figure 3. The current competitors and the customers will be
discussed in the subsequent sections along with their defining attributes towards determining
targeted market segments.
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Figure 3. Five Market Forces with General Examples for BioMAN
2.2.1 BioMAN Competitor Attributes
The current competitive environment of BioMAN (within the central box of Figure 3)
encompasses identifying competitors, their objectives, capabilities, and other relevant
details.(12) By analyzing these competitor attributes, an understanding of the market can be
developed and visualized.(10) Additionally, the extent of overlap and/or complements with the
BioMAN offering and those of others in the market can be determined.(8)
Specific BioMAN competitors within the context of a market broadly defined as
"interdisciplinary research in technology, policy, and business relevant to biomanufacturing"
were identified in three ways:
1. The categories presented within the "current competitors" force box of Figure 3
2. Online searches for biomanufacturing research centers
3. Interview with Stacy Springs, Ph.D., BioMAN program director
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Within the area of academic consortia, the following competitors and their characteristics in
the areas of location, origination date, stated objectives, consortium members, and resources
(facilities, personnel, funding) were identified to the extent possible. The consortium are
ordered based on geographic proximity to BioMAN (Cambridge, MA):
Tufts Center for the Study of Drug Development (Tufts CSDD) (13)
o Location: Tufts University, Medford, MA
o Origination Date: 1976
o Objectives:
* To monitor and report on the development, regulation, and utilization of
new drugs and biopharmaceuticals.
* To explore the economic, legal, scientific, and public policy issues
affecting pharmaceutical and biopharmaceutical innovation worldwide.
* To serve as an information resource on the development and review of
new therapeutic agents.
* To sponsor public forums and conferences which bring together the
perspectives of government, industry, academia, and public health
advocates.
* To raise the level of national and international debate on issues related
to new drug and biotechnology product development and regulation.
o Consortium Members:
* Medium and large pharmaceutical companies (e.g. Wyeth, Eli Lilly, Daiichi
Sankyo)
o Resources:
* Facility: office space
* Personnel: medical professionals, pharmaceutical business strategists,
attorneys
* Funding Sources: consortium members (55% of total), foundation
support, grants for commissioned projects, registration fees for courses
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and conferences, and subscription fees for certain Tufts CSDD
publications.
Massachusetts Biomanufacturing Center (MBMC) (14)
o Location: UMass-Lowell, Lowell, MA
o Origination Date: Announced 2007
o Objectives:
* Complete applied research problems that improve the quality, cost and
productivity of large-scale biomanufacturing production
* Areas for incremental advances include improved process control
of bioreactors, increased expression levels, prolonged cell
lifetimes and faster cell growth rates (cell cycle times) and
disposable and new purification technologies
* Areas for breakthrough programs include perfusion reactors to
convert batch processes to continuous ones, developing yeast as a
replacement for mammalian cell cultures and using E. coli to
create antibodies in soluble form.(14)
* Help biotech companies transition from R&D to validated, cGMP-
compliant manufacturing processes
* Student education and training (Ph.D., certificate programs)
o Consortium Members:
* Industrial: Nova Biomedical, Antigenics, Cambrex, Genzyme, Invensys,
Millenium, Wyeth(15)
* Academic: UMass Dartmouth, Worcester Polytechnic Institute, Tufts
o Resources:
* Facility: planned $80M, 97,000 sq.ft. emerging technology and innovation
center (construction currently delayed by issues with financing)(16)
* Personnel: faculty leadership with expertise in chemical engineering and
cell biology
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* Funding sources: state, federal and university funding(17), Massachusetts
Technology Collaborative's John Adams Innovation Institute (15)
* Northeast Biomanufacturing Center and Collaborative (NBC 2)(18)
o Location: New Hampshire Community Technical College, NH
o Origination Date:2005
o Objectives:
* Sustain an alliance of community colleges to prepare a 21st century
technical workforce in biomanufacturing
* Develop curricula and hands-on SOPs to support biomanufacturing
education and training
* Collect data from the Northeast region on the number of students
entering training in biomanufacturing and that go on to work in the field
o Consortium Members:
* Industrial: broad range of tens of biotech companies (from Abbott to
Wyeth)
o Resources:
* Facility: Laboratories and classrooms at participating community colleges
* Personnel: Faculty at participating community colleges
* Funding Sources: National Science Foundation - Advanced Technological
Education Center (four years, $3M total)
* Biomanufacturing Research Institute and Technology Enterprise (BRITE)(19)
o Location: North Carolina Central University, Durham, NC
o Origination Date: 2006
o Objectives:
* Research focus in the areas of drug discovery and manufacturing
technology
* Education/training of students (B.S., M.S., Ph.D.)
o Consortium Members:
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* Industrial: Biogen Idec, Merck, GlaxoSmithKline, Bayer Corporation,
Novozymes
* NC Nonprofits: NC Biolmpact, GoldenLEAF, BTEC, BioNetwork,NC
Biotechnology Center, NC Bioscience Organization
o Resources:
* Facility: 52,000 sq. ft. dedicated research and office facility
* Personnel: Twelve research faculty
* Funding Sources: The Golden LEAF Foundation of North Carolina ($20M)
Biomanufacturing Training and Education Center (BTEC) (20)
o Location: North Carolina State University College of Engineering, Raleigh, NC
o Origination Date: 2008
o Objectives:
* Provide educational and training opportunities to develop skilled
professionals for the biomanufacturing industry
o Consortium Members:
* Undetermined
o Resources:
* Facility: 82,500 sq. ft. dedicated laboratory and classroom space
* Personnel: Faculty in chemical engineering, microbiology, bioprocessing
* Funding Sources: The Golden LEAF Foundation of North Carolina, training
contracts (e.g. FDA contract to train inspectors)
* Center for Process Analytical Chemistry (CPAC) (21)
o Location: University of Washington, Seattle, WA
o Origination Date: 1984
o Objectives:
* The investigation of new measurement approaches based on the
miniaturization
* The investigation of issues related to the integration of process
measurement with process modeling and control
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* The improvement of mechanisms for interaction, collaboration, and
communication of Center activities, research programs, government
agencies, and the general measurement and control community
o Consortium Members:
* Industrial: wide range of processing companies (from ABB to Wyeth)
* Government: NSF, National Labs
o Resources:
* Facility: Undetermined
* Personnel: Twenty-six associated faculty in chemistry, electrical
engineering, etc. at UW and elsewhere (Delaware, UC-Davis, etc.)
* Funding Sources: Sponsorship from industrial consortium members
By detailing the competitors and many of their defining attributes, contextual positioning of the
competitors based on their attributes can be completed.(10) By positioning the competitors by
attributes, direct competitors and potential collaborators can be identified. For the specific
competitors described above, possible attributes for inclusion in such an analysis include:
* Extent (or fraction) of focus specific to biomanufacturing
* Focus on academic research vs. training workers
* Research focus on management vs. technical research
* Availability of custom projects for industrial consortium members
* Geographic location
* Industrial vs. non-profit financial sponsorship
* Relative size of initiative (as measured by publications, faculty, facilities)
A summary of these identified attributes applied to the six academic consortium competitors is
presented in Table 1. This tabulation clarifies that, as BioMAN is primarily interested research
(and perhaps both research and training), neither of the two primarily training consortium
(NBC 2 and BTEC) are direct competitors to BioMAN. Depending on the BioMAN capabilities and
targeted market segment(s), it may be is possible that these two organizations or ones similar
to them could be considered for collaboration efforts.
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Table 1. Summary of Identified Attributes of Academic Consortium Competitors
UOD
Research Both Training Research Training Research
Some Yes N/A Undetermined N/A Some
.... ........
Afll~
... 
10
Medium Large Small Large Large Large
With the four remaining academic consortia being considered as potential direct competitors to
BioMAN, one way to represent their placement in the attribute space is graphically with a
perceptual map. (10) All seven of the relevant attributes for those four consortia are plotted in
Figure 4, which shows a number of key summary results:
o Tufts CSDD is strongly differentiated from the three others by its placement in the area
of management research
o MBMC is differentiated by its placement in the area of technical training and availability
of custom projects for industrial partners
o None of the competitors have a primary focus in management training, although Tufts
CSDD does offer an Institute for Professional Development which offers three one-day
courses of instruction annually(22)
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Figure 4. Perceptual Map of Four Identified BioMAN Direct Competitors
Another potential type of competitor to BioMAN is the internal research and development
within industry. The details of relevant objectives to internal industrial biomanufacturing
research are expected to be specific to each company. Given this variability in the objectives of
this set of potential competitors, the context and rationale of customer decisions to enter into
or join academic consortia (addressed in the subsequent section) is an important part of
determining attractive market segments.
2.2.2 BioMAN Customer Participation Rationale
Academic consortia typically intend to attract industrial and/or non-profit (foundations,
government) as customers to fund and provide other resources towards conducting the
intended work. The rationale for forming consortia has been previously identified by Doz et al
based on data collected on the formation process of 53 R&D consortia.(7) The formation
rationale is described as cross-firm environmental interdependence (product standardization,
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external threats) of the participants and the formation process facilitated by a triggering entity
that can ensure fair share of costs and benefits to participants.
The rationale for an individual firm to participate in consortia has been researched both
quantitatively and qualitatively over a variety of industries. For example, Baldi et al(23)
examined business-to-business consortia in the automotive industry (to which some large
automotive companies elected to join and others did not). In that research, it was found that
driving forces for companies to elect to join a consortium centered around the following
themes with the advantages and disadvantages (with modifications adapted from Dagnino et
al(24)) of a generic consortium cited:
o Cost economics
o Advantages: lower cost per company to achieve objective; aggregating demand
lowers any relevant procurement costs
o Disadvantages: difficult to build and set-up costs can be high; cost of integration
back into the company can be high
o Resource dependence
o Advantages: pool complementary expertise to create unique knowledge
o Disadvantages: dependence on a competitor might evolve
o Stakeholder theory:
o Advantages: consortium members become committed to the initiative (e.g. a
standard)
o Disadvantages: excluded companies might show averse reactions
o Organizational learning
o Advantages: consortium participants can learn from one another
o Disadvantages: sharing of confidential and/or valuable information; new
intellectual property may reside in the consortium
o Strategic choice
o Advantages: realize competitive advantages; accomplish complex tasks
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o Disadvantages: advantages available to all participants; consortium management
and flexibility is complex
Additional insight into the perceived value received by firms for participation in consortia can
be found from the marketing material provided by existing consortia. The value identifying in
these marketing materials typically are the research projects outcomes, sharing risks, and
connecting to others in the industry (including government employees). For example, the
Biomarkers Consortium markets the following value to its potential consortium members
towards having "a greater voice in the growing world of personalized medicine"(25):
* Shape consortium project concepts into executable projects.
* Share in the risks and rewards of developing these often-times costly, scientifically
challenging projects.
* Develop relationships with colleagues from a variety of sectors interested in identifying and
developing biomarkers.
* Receive frequent updates on the status of the consortium's efforts, its projects, and new
opportunities for involvement.
* As a group, elect four representatives to serve with NIH, FDA, and others on the consortium
executive committee.
As another example, the advantages to industrial partners in the Dundee Kinase Consortium are
described as: (26)
o Access to Know-how from >70 world class scientists
o Screening facility vs. panel of kinases
o Electronic Information storage / transfer
o Production of proteins & biological reagents
o Custom synthesis of antibodies
o Information on new drug targets
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Representatives from GlaxoSmithKline (GSK), a pharmaceutical company that is a Dundee
Kinase Consortium member, have also published their perception of value to industry in
participation in that consortium:(3)
o Information on new drug targets
o Access to Know-how from >150 world class scientists
o Tangible deliverables for industry:
o Screen facility vs. panel of kinases
o Electronic information storage / transfer
o Production of proteins and biological reagents
o Custom synthesis of Ab's and transgenics
Given that the dates of origin (2004 and 2008, respectively) of these two perspectives on the
value of the Dundee Kinase Consortium are not significantly different than one another and
that the size of the consortium did not change significantly over that time, it is noteworthy that
the GSK description apparently values the interaction with researchers from others companies
as it lists 150 scientists (this number would likely cover the Dundee researchers plus the
participating researchers from other companies) whereas the Dundee number of 70 is
comparable to the number of Dundee researchers. Also of note is that GSK has explicitly
outlined those deliverables that are perceived to be tangible.
GSK also provided their general rationale for electing to participate in consortia: (3)
* Address large research challenges
* Achieve a critical mass
* Access to:
o Complementary skills and/or technologies
o Academic lateral thinking
o Multi-disciplinary problem solving
Specific quotations from industrial partners in the Tufts CSDD (selected by Tufts for inclusion on
the website) also focused on the tangible returns on their participation:(13)
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o "I rely heavily on the objective industry benchmarking and performance metrics
generated by the Tufts Center for the Study of Drug Development. This information is
critical for assessing our own performance and targeting important areas for growth and
improvement." - Wyeth
o "The data generated by the Tufts Center are vital to us in our efforts to improve R&D
performance and yield. Moreover, the work of the Tufts Center has been enormously
influential in political and regulatory debates worldwide on issues related to
pharmaceutical innovation." - Eli Lilly
In interviews with Stacy Springs, Ph.D., director of BioMAN, regarding the themes that current
and potential industrial BioMAN participants cite as important in their decision to join BioMAN,
the following themes surfaced:
o Extent to which BioMAN research is aligned with the strategic research plan of the
company
o The perceived importance of futures planning around a shared vision
o Connection to MIT (e.g. as an alum or past MIT consortium sponsor)
o Geographic proximity to MIT
o Connection to safe haven regulatory discussions
o Networking opportunities with others in industry including FDA personnel
o Economic climate (current recession is impacting industrial partners)
Across the academic research on R&D consortia, marketing materials from current consortia,
industrial partners' feedback on consortia value, and interviews with the current BioMAN
director, the following two general themes relevant to BioMAN appear:
o Tangible research value to the industrial partner
o Networking opportunities within the industry (particularly with individuals in other
companies and in government agencies)
The tangible results that industrial partners are looking for involve either benchmarking data
for inter-firm comparisons and goal-setting or technologies for practical use. In the case of
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technologies for practical use in biomanufacturing, experience with CAMP and the line of
questioning from industrial partners to Professor Alan Hatton's presentation on magnetic
separation at the March, 2009 MIT ILP Biomanufacturing Conference suggest that the industrial
partners need the following questions answered with reasonable certainty:
o Can the technology be applied to an industrially relevant system?
o Is it effective for our types of products? Can it be scaled?
o Is the technology safe for the product, the operators, and the equipment?
o Is purchase, deployment, and validation cost effective?
The challenges associated with answering these questions theoretically in a convincing fashion
usually drives towards the use of pilot scale testing facilities in advance of industry acceptance
of a new technology.
In addition to industrial partners, another set of potential customers are non-profit
organizations committed to academic research. These non-profits include private foundations
(e.g. Kauffman, Sloan, Gates) and government agencies (e.g. NSF, FDA, NIH). Each individual
non-profit has a mission-specific objective (e.g. global health for Gate Foundation) and is
interested in systemic, general research questions that can be applied at a broader level than
an individual firm. These non-profits typically sponsor research either at the project/program
level or at the individual investigator level. Many of the government agencies are currently
increasing funding available for science programs through various stimulus packages.
Specific non-profit sponsors that are well aligned with the intended research of BioMAN
include:
o Alfred P. Sloan Foundation: original research and education in technical areas(27)
o Potential focus on biomanufacturing industry and associated economic systems
performance (see Chapter 3)
o Gates Foundation: improving global health(28)
o Potential research program: enabling inexpensive transport of biological
products to remote locations (see Appendix A)
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o Grand Challenges: working in collaboration with Gates Foundation(29)
o Requests for proposals in specific research areas are solicited twice annually.
Initial grants are in the amount of $100,000 and successful projects have the
opportunity to receive a follow-on grant of $1 million or more.
o Broader NIH: Roadmap Transformative R01 Program (30)
o Focus areas of potential interest (e.g. Novel Protein Capture Reagents)
o NIH New Innovator Award - awarded to individuals(30)
o Up to $1.5MM over 5 years
o NIH Pioneer Award awarded to individuals (30)
o Focused on new and emerging research areas
In attempting to serve both types of customers (industrial, non-profit) simultaneously, a
challenge arises at the interface of generality vs. specific ("custom") research. However, as
mentioned previously, two noteworthy relevant consortia (Dundee Kinase, Tufts CSDD)
complete this approach by engaging both types of customers in longer-term transformational
research while provided custom near-term projects and educational opportunities for industrial
partners.
2.3 BioMAN Capabilities
The current BioMAN organization is an integration of individuals each with their own expertise,
or core competences.(8; 31) However, one weakness of the BioMAN consortia being composed
of individuals with their own, independent expertise is that BioMAN and these individuals have
potentially competing core products in a similar channel ("channel conflict"). An individual
marketing their own research may be attempting to directly attract the same resource
source(s) as BioMAN.(10) Ways to overcome this potential channel conflict include 1) focusing
BioMAN on projects that are sufficiently interdisciplinary and collaborative (e.g. systems based)
not to directly conflict with research of individuals; and 2) creating long-term engaging research
contracts with BioMAN researchers in the consortium.
Both the BioMAN management and the capabilities of the BioMAN affiliated researchers have
the capability to design and enact interdisciplinary and collaborative research programs.
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Representatively, the individuals in the MIT BioMAN community that have participated in
activities to date and/or expressed interest in doing so represent a wide range of expertise and
potential for projects attractive to BioMAN customers. The MIT BioMAN community expands
beyond MIT to include collaborators with relevant subject matter expertise and research
interests. In completing a review of their capabilities, three areas of core competence (32; 9)
emerge:
o Economics, Management, and Policy
o Biochemical Engineering
o Optics and Sensors
With the recent movement of CBI as a research initiative within the MIT engineering systems
division (ESD),(33) the emerging collaborations between BioMAN and faculty with expertise in
systems engineering have the potential to blossom. Systems engineering projects are
interdisciplinary and collaborative as they require both detailed subject matter expertise and
broad, mathematical constructs in which to frame the details.
Three significant lacking resources for BioMAN projects are:
o A history of demonstrated projects
o Relevant historical data sets
o A biomanufacturing facility in which to test potential new technologies
The first lacking resource is largely mitigated by the branding of MIT as a research center of
excellence. Depending on the type of research project, the other two lacking resources may be
able to be added to the BioMAN capabilities through collaboration.
2.4 Marketing Strategy
The marketing strategy is dependent upon the competition, the customers, and the
organizational capability and is therefore always dynamic and prone in error.(10) An estimation
of market segments that can be logically targeted by BioMAN and product positioning within
those segments are described in the following subsections.
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2.4.1 Targeted Segments
The potential sources of segmentation of the market are displayed in the table of attributes
(Table 1) gleaned from an analysis of the current competitors of significance and the associated
perceptual map of Figure 4. Of the seven attributes, four of the attributes are not
independently selected for BioMAN, namely:
o Focus on biomanufacturing: this will be the only focus of BioMAN
o Geographic location: BioMAN headquarters and regular meetings will be at MIT
o Financial sources: pursued sources will be interdependent upon the research agenda
o Size: will be dependent upon the financial resources
The remaining three attributes (research/training, management/technical, availability of
custom projects) define the possible market segments and set the research strategy for
BioMAN. With the current set of BioMAN available or lacking resources (ESD faculty with
expertise in systems, MIT technology expertise branding, uncertain funding sources, and no
faculty solely dedicated to biomanufacturing research) and the current shrinking of availability
of funds from industrial partners, taking on significant commitments in the areas of training
and/or custom projects would risk utilizing a small amount of resources towards a few small
projects that will not have direct continuity into the future. It is therefore most logical to
currently pursue the market segment of systems-based interdisciplinary research in
management and/or technical arenas that can be supported financially by non-profit entities
and supported conceptually and with data by industrial partners. This is depicted in Figure 5
where the four identified direct competitors have been shaded out and BioMAN has been
placed in the market map. To the extent that this pursuit becomes successful and enables the
formation of a research team of significant size and expertise to branch out, then taking on
training and/or custom project opportunities would be valuable towards strengthening
relationships with industrial partners.
Reuben Domike MBA Thesis Page 28 of 60
Technical anagement
.' Legend
.-Extent of Location
.BioMfg Focus?
Training .. Al Funding
Size Source
Custom Projects?
(by stoplight color)
Figure 5. Perceptual Map with the Inclusion of BioMAN in the Market
In order to achieve success in this location of the market, BioMAN will become more dependent
upon non-profit funding sources (foundations and government agencies) than BioMAN
currently is. This will require BioMAN managerial effort invested in determining the objectives
of relevant foundations and government agencies.
One recent example of a successful relevant niche consortium, the C-Path Consortium (which
works with the FDA on its Critical Path Initiative) advertises the following specific selection
criteria that are well aligned with the objectives of its partners: (34)
* The problem (or the opportunity) must be important to the public health and one that was
identified in the Critical Path Opportunity List or one subsequently identified by FDA
scientists at multiple levels.
* The project must be acknowledged by the industry as important and therefore one that
multiple companies are willing to dedicate the time and efforts of their employees.
* There must be a "neutral source" of funding for C-Path to rise to support the project.
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2.4.2 Product Positioning
The positioning of the BioMAN product should be clear both to constituents internal to the MIT
biomanufacturing community and to potential resources source(s). Additionally, in the
positioning of the product to external constituents, the concept that BioMAN complements
existing biomanufacturing efforts in the region (specifically Tufts CSDD and MBMC) should be
articulated when helpful. (10) Moving forward, the potential for project-specific collaboration
with these two entities would help BioMAN achieve research excellence. The researchers and
data available through Tufts CSDD could prove valuable to macroscopic economic performance
research conducted through BioMAN. The potential facilities and pilot scale manufacturing
expertise at MBMC could enable demonstration of new technology developed through BioMAN
in industrially relevant settings.
2.5 Actionable Recommendations
Leveraging the market analysis around competitor attributes, customer rationale for
participating in BioMAN, and the BioMAN capabilities, the following recommendations result:
* Internally market the value of interdisciplinary solutions approach to attract potential
collaborators within the MIT biomanufacturing community (at MIT and beyond)
* Enable the possibility of taking of ideas from idea/laboratory bench to pilot
demonstration
o Consider partnering with Massachusetts Biomanufacturing Center (MBMC) to
leverage complementary activities, geographic proximity, and their early stage of
formation (which may give BioMAN some influence in the MBMC design and
objectives)
* Pursue research projects that have potential for both tangible results to industrial
partners and connection to systematic challenges in biomanufacturing
o Enables simultaneous pursuit of value creation to industry and non-profit
funding sources (e.g. foundations, government agencies)
o Continue to pursue research project specific collaborations across disciplines
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* In the future, consider developing academic content in the area of biomanufacturing
management (e.g. student programs, executive education programs) as this appears to
be an available market and is well connected to the MIT brand and faculty capabilities
* In the future, consider marketing custom projects to enhance tangible value creation for
industrial partners
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3 Specific Example of a Proposal to a Potential New Resource Source
The following is a fully developed example of an interdisciplinary, systems-based research
program that appears to be well suited to receive support from a non-profit research sponsor
with interest in understanding economic systems (e.g. the Alfred P. Sloan Foundation of New
York).
3.1 Background: Research Motivation and Intent
Biologics are the fastest growing sector of the pharmaceutical industry with significant growth
potential projected for the next 10 years.(35;36;37) Costs associated with the production of
biopharmaceuticals have increasingly led companies to explore global supply chains for the
manufacture of biologics by outsourcing, owning facilities, and/or establishing joint
manufacturing ventures in low cost areas of the world ("off-shore") instead of manufacturing in
close geographical proximity to their innovation and discovery centers.(35;36)
Recent studies focused on small molecule pharmaceuticals in areas of off-shoring(36) and
global innovation(38) demonstrate the importance of taking both a global and systems
perspective of manufacturing. Biopharmaceuticals have special concerns in manufacturing
complexity, product fragility, unproven analytical techniques, and cold chain logistics for
storage and distribution.(39)
It is the intent of this research program to develop a detailed understanding of the current and
future states of biopharmaceutical manufacturing in the context of commercial strategy, global
supply chain, and evolving landscape. This program will be accomplished by bringing together
subject matter experts in areas of biopharmaceutical manufacturing, economic systems
models, the role of regulation, and regional variability.
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3.2 The Capabilities of M.I.T. Center for Biomedical Innovation
The Center for Biomedical Innovation (C.B.I.) at the Massachusetts Institute of Technology
(M.I.T.) is an established leader in collaborative research at the interface of academia, industry,
and government regulator. With this framework already in place, the research program will
proceed quickly and effectively under the academic guidance of principal investigators,
consultants, and advisors. Research Framework, Approach, and Methodologies
To develop a detailed understanding of the current and future states of biopharmaceutical
manufacturing, this research program intends to use the framework depicted in Figure 6. This
framework is designed to enable the examination of integrated economic systems models of
commercial strategy, supply chain optimization, and anticipated changes in the context of
regional effects and regulation. The approach and methodology associated with each of these
topics is addressed in the following sections.
U) O
Economic Systems Models
Figure 6: Research Framework for Biopharmaceutical Manufacturing
3.2.1 Commercial Strategy
The commercial strategies of biopharmaceutical manufacturing are strongly dependent upon
regional economic incentives (e.g. taxes, labor costs, required capital), core competencies of
the companies, appreciation of quality standards, manufacturing capital cost risk mitigation,
transportation challenges, communication, and intellectual property protection.(35) As
depicted in Figure 7, the influence and the impact of these commercial strategies are reflected
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in the economics of the value chain, extent of integration within a company's
biopharmaceutical manufacturing, and the physical location of the manufacturing. The
intended research in each of these specific areas is described in the following sections.
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Figure 7: Context of Commercial Strategy Research
3.2.1.1Economic Value Chain in a Global Innovation System
Innovation is widely held as the key to the sustained competitiveness of the U.S. As
biomanufacturing supply chains combine a range of geographies, integrated technologies, and
innovative approaches, it is unclear who is capturing the resulting value. As has been done
recently for another globally innovated product, the iPod,(6) it is the intent of this research to
develop an understanding of the economic value creation across the product lifecycle and
thereby determine where innovation within biopharmaceutical manufacturing is sustained (as
demonstrated by sustained profit).
This work will involve defining a framework of the biopharmaceutical manufacturing value
chain and leveraging specific case studies within that framework to quantitatively determine
innovation sustainment. Consistent with recent studies,(6) the approach in this framework will
be a value map built from raw materials through to the customers that incorporates geographic
locations towards de-convoluting both which innovators and which countries are receiving the
value. The data intended for quantifying the value map includes gross profit data available
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from annual reports of publicly traded companies, component prices from industry analyst
reports, and validation from interviews with participants in the value chain.
The specifics of biopharmaceutical manufacturing will be compared to small molecule
pharmaceutical manufacturing and other relevant high-volume, global manufacturing,
innovative industries (automotive, electronics).(7) The quantitative value chain framework will
also enable a consistent paradigm for describing other aspects of commercial strategy, supply
chain optimization, and anticipated changes within this research program.
3.2.1.2Integrated vs. Disintegrated Global Posture
Building on recent data and findings from the semiconductor industry regarding the
performance implications of outsourcing decisions,(40) this aspect of the research program will
further the value chain framework by determining interconnectivities within the product
lifecycle, both from theoretical and data driven perspectives. In the case of semiconductors,
recent research suggests that internal knowledge and dependencies in product and process
development yields net commercial gains for maintaining internal capabilities.(40) Without this
systems perspective, outsourcing appeared more attractive in many cases. Recent research in
the pharmaceutical industry suggests possible similarities to the semiconductor industry as
contract manufacturing facilities have been documented to generally correspond to inferior
performance metrics(41) and the knowledge created from firm experience has been shown to
be significant.(42)
This methodology of examining the impact of extent of integration on commercial performance
in the context of biomanufacturing will be extended to both biopharmaceutical development
companies and biopharmaceutical contract manufacturing organizations. This will be
accomplished through extensive data collection with industrial partners and analysis in the
context of the full economic systems models.
3.2.1.3Manufacture Location Decisions
It is the intent of this subset of the research to quantify the impact of regional economic and
political volatility, particularly in areas of interest for off-shoring and integrate these findings
into the comprehensive economic systems model. This is described in detail in Chapter 4 as an
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example of an approach to an interdisciplinary project attract to both non-profit sponsors and
industrial partners.
3.2.2 Supply Chain Optimization
Supply chain strategies typically focus on the interconnection, competition, and associated risks
of key drivers such as:(43)
* Cost pressures (e.g. capital, labor, and tax efficiencies)
* Variability in supply chain quality
* Variability in regional regulation
Recent contamination-related deaths associated with the biologic drug heparin indicate that
there is significant potential for improved supply chain optimization by utilizing a
comprehensive risk-based economic systems model for biologics.(39;44) Failure to establish
and maintain a robust supply chain will reduce consumer confidence in the use of biologics and
the competence of the associated regulatory agencies.
As depicted in Figure 8, the focus of the economic systems model for supply chain optimization
will encompass security, safety, and resilience in the framework of regional effects and the role
of regulation. These three aspects are described in sections below.
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Figure 8: Context of Supply Chain Optimization Research
3.2.2.1Safety of the Biologics Supply Clihain
In the face of potential trade-offs between cost and safety, the ability of the supply chain to
deliver safe biologic products is critical to patients who could suffer morbidity or mortality from
tainted drugs. As described in recent research:
"Cost constraints are forcing enterprises to outsource and off-shore functions once
performed within the safe environs of an FDA-regulated manufacturing facility. Movement
of.. manufacturing to lower-cost locations, in some cases has resulted in reduced quality
controls, re-introducing risk factors that haven't existed for decades. The most recent debacle
related to the processing of pig intestines-a starting ingredient for the production of
heparin, a commodity that is used in a high percentage of medical and diagnostic
procedures-highlighted what appears to be the tip of an iceberg." [Reed, 2008](45)
The systems-based models developed in this research will enable ongoing risk-based quality
and robustness assurances with considerations including:
* Importance of direct access to monitoring data from suppliers
* Financial health and political risks of suppliers
* Interdependence of suppliers
* Patient data monitoring for unusual events
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The approach to accomplish this intent is to integrate existing data on safety standards, safety
violations, regulatory policies, and decision making priorities.
3.2.2.2Integrated Approach for Addressing Counterfeits
Globalization of the supply chain has increased the presence of counterfeits as depicted in
Figure 9.(46) Counterfeit drugs pose health risks to patients and loss of revenue for
pharmaceutical firms.
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Figure 9: Counterfeit Drug Cases Opened by OCI in the Past Twelve Years(46)
Additionally, the variation in regional regulation around security is significant as exemplified in
the following list of emerging state, national, and international requirements:
States:
- Individual state pedigree requirements
- CA required electronic pedigree, manufacturer through pharmacist and requires
serialization at saleable unit by 2015
U.S. National:
- FDAAA Sec. 913 Calls on FDA to develop a standard numerical identifier (SNI) by
March 27, 2010
- Possible legislation in 111 th Congress: Buyer-Matheson
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* International:
- WHO World Health Organization's International Medical Products Anti-
counterfeiting (Impact) Task Force
- EU Proposal: Directive of the European Parliament and the Council
- Amending Directive 2001/83/EC to prevent entry of falsified medicinal products
(e.g. identity, history) into the legal supply chain
The models developed in this research will specify a system solution to combat challenges of
counterfeit biologics in global supply chains. Consideration will include techniques such as:
* Serialization to enable traceability
* Secure e-pedigree exchange
* Supply chain event data networks
* "Point of Entry - Point of Exit" validation system
3.2.2.3Resilience to Disruptive Events
The complete biopharmaceutical manufacturing process is typically complex; with many
manufacturing stages (spanning time and space) and long production cycles (hundreds of days
is common). Given this high level of complexity, the industry consolidates expertise and
capability into central facilities and is less invested in secondary components of the supply
chain (e.g. suppliers, storage, transport). As a result, the resilience of the supply chain in
providing patient-critical product in the case of significantly disruptive events is expected to be
fragile:
"In most cases secondary suppliers, storage and transportation are not well addressed.
Because these supply chain roles are increasingly played by globally dispersed organizations,
there is increasing vulnerability that needs to be addressed." [Reed, 2008](45)
Leveraging existing models of resilience in supply chain optimization and lean manufacturing
concepts, strategies that identify optimal trade-off between flexibility and fixed cost required to
achieve that level of flexibility will be developed. To the extent that flexibility and redundancy
is built into the system, the likelihood of having a robust and resilient supply chain increases
and both greater patient care and greater profit can be realized in the case of adverse events.
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Specifically, the approach will include working with industrial partners to determine:
* The extent of flexibility in place today. Both the current state and the associated
rationale with comparisons to other relevant industries (automotive, electronics).
* Control location of work in progress. Considering the physical location of work in
progress relative to risk-based models of adverse events in the model of resilience.
* Reduce cycle time. Reducing cycle time is a key to increasing resilience of the supply
chain. It can be directly achieved by lean manufacturing concepts and better utilization
of workers, equipment, and workstations.
3.2.3 Anticipated Changes
Three changes that have been identified as having potential to significantly alter the landscape
of biopharmaceutical manufacturing are: the role of emerging markets, new technologies and
personalized medicine, and the economics of regulatory compliance. These are depicted in
Figure 10 and described in the following sections.
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Figure 10: Context of Research on Anticipated Changes
3.2.3.1Role of Emerging Markets
Beyond the cost advantages of manufacturing biopharmaceuticals in emerging markets, some
North American and Western European companies perceive a strategic advantage in ease of
Reuben Domike MBA Thesis Page 40 of 60
global delivery as the consumption of biological products in emerging markets increases.
Additionally, recent research suggests that emerging market companies with manufacturing
expertise (e.g. contract manufacturers) are engaging in reverse-off-shoring to "develop in-
house R&D capabilities with the intent of becoming major global players."(36) These emerging
market companies are leveraging local government initiatives supporting biotechnology and
hiring internationally trained scientists and engineers.(36) The significance of these trends on
biopharmaceutical manufacturing and associated employment of U.S. scientists and engineers
will be the focus of this aspect of the research program.
This aspect of the research will consider scenarios of the role of emerging market and the
relevant impact on the commercial strategy and supply chain frameworks developed.
Specifically, the research will investigate the following:
* Impact of regional economic and political volatility (described previously as part of the
Commercial Strategy component of this research program)
* Details of biopharmaceutical employment trends in emerging market companies and
western companies
o The trend is described in recent research: "Although there may not be an
imminent threat to American leadership in technology, the number of young
professionals in emerging markets is growing by 5.5% annually, while growth in
developed countries is only 1%."(36)
o With the impact described as requiring "more statistical data on employment
and demand for engineering positions broken down by academic majors,
degrees, and functions in the industry both in the US and abroad... to produce a
clearer picture of how off-shoring will impact the science and engineering
workforce in the US pharma industry."(36)
* Details of trends in reverse off-shoring leveraging recent data and conducting interviews
with contract manufacturers and government officials
o Determine the extent to which utilization of off-shore contract manufacturers is
expected to change
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o The impact of government-sponsored biotechnology and education initiatives in
emerging markets
3.2.3.2New Technology: Disposables and Personalized Medicine
The impact of emerging technology on the commercial and supply chain frameworks of
biopharmaceutical manufacturing will be investigated in the context of two specific
technologies: disposables and personalized medicine. Disposable manufacturing equipment
pieces have the potential to enable both distributed manufacturing and reduced capital
expenditure. In the context of manufacturing, personalized medicine would reduce batch sizes
and increase the value of manufacturing flexibility and product customization.(47)
It is the intent of this aspect of the research program to evaluate future scenarios associated
with these two technologies to determine their impact on how and where biopharmaceutical
manufacturing will be done. These two technologies would be representative case studies of
the role of new technology on the biopharmaceutical manufacturing landscape and provide
insight into expectations and hurdles.
3.2.3.3Economics of Regulatory Compliance
As small and medium sized biopharmaceutical firms move towards global supply chains, their
ability to meet regulatory expectations is undetermined. Leveraging recent F.D.A. inspection
history data for every pharmaceutical manufacturing facility that has shipped product to the
U.S.A., this aspect of the research will determine the importance of firm size, experience, and
financial status on inspection performance.(41)
Additional investigation into the economics associated with ensuring regulatory compliance of a
global supply chain will be undertaken to provide a rationale for small and medium
biopharmaceutical companies considering use of a global supply chain. These economic data
will be determined in collaboration with the M.I.T. C.B.I. industrial partners and in the
frameworks established in the commercial strategy and supply chain optimization aspects of
this research program.
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3.3 Outcomes of the Research
Intermediate outcomes of the research include continued and extensive interaction between
academia, industry, and the U.S. F.D.A. on issues critical to the economics and safety of
biopharmaceutical manufacturing. These will include topical roundtable discussions, working
papers, recommendations, and collaborative research.
The deliverables of the research program include a series of academic papers describing the
economics systems models and their underlying theory and supporting data. These models
provide a framework to use in structuring activities to ensure global safety across the
biopharmaceutical supply chain. The deliverables further include detailed decision criteria for
off-shoring biopharmaceutical manufacturing efforts. Additionally, these criteria will be framed
to provide guidance to policymakers in designing incentives for specific activities within
biopharmaceutical manufacturing.
Activities under the research provide for training of graduate and post-doctoral students. This
training builds a knowledge base in economic systems models, supply-chain logistics, regional
variability, and the role of regulation.
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4 Approach of a Research Project: Biomanufacture Location Decisions
in the Prospect of Regional Volatility
It is the intent of this subset of the research to quantify the impact of regional economic and
political volatility, particularly in areas of interest for off-shoring and integrate these findings
into the comprehensive economic systems model.
4.1 Background of Regional Volatility
A number of factors influence the likelihood of regional volatility which, in turn, may or may not
impact the business operations or costs associated with biomanufacturing. Examples of the
influencing factors, institutional structures, and events that may trigger significant volatility are
depicted in Figure 11. An underlying influencers analysis model will be employed, as has been
done in previous research,(48;49) to identify and quantify impact on different types of foreign
investment due to regional volatility. This model will specifically build on:
* Histories and projections of economic and political volatilities and the relevant impact
on a variety of types of foreign investment in low cost regions of current interest (e.g.
China, India, Malaysia, Latin America)
* A region specific approach to gain insight into the specifics of the regions of current
interest
* Histories of impact of regional volatility on small molecule off-shoring and off-shoring in
other industries
A simple example of minor economic volatility is recent wage increases in Asia: operating costs
for technology off-shoring to India in 2004 was found to be approximately 20% of that in the
United States, but wages across the board from accountants to engineers have increased in
excess of 10% per annum due to rising demand since that year and are now closer to 30% of
that in the United States.(50)
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Figure 11. Influencers, Structures, and Events that may Impact Regional Volatility
Based on the research on volatility impact and the cost structure associated with
biomanufacturing (provided by M.I.T. C.B.I. industrial partners), a stochastic model of probable
scenarios and the resulting economic impact will be developed. An additional aspect of the
influencer analysis model will be explicit approaches for risk mitigation of key influencers
through detection methodologies.(51) There are parallels in this approach to quality by design
(cause and effect, historical precedents, design space estimation, failure mode and effects
analysis).
Industrial members of the M.I.T. C.B.I. community have agreed to provide data and interview
access to develop case studies of off-shoring decisions. In particular, the industrial members
will provide:
* Completed decisions and associated rationale (as available) regarding off-shoring for
biologic products
* The manners in which volatility has been incorporated in previous off-shoring or similar
decisions
* Cost structures of existing off-shoring activities for both small molecules and biologics
* Intermediate reviews of ongoing research
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4.2 Framing the Project
4.2.1 Guiding Information from the Industrial Sponsor
In preliminary discussions with the industrial sponsor, the following general observations were
made regarding manufacture location decisions:
* The decision regarding the manufacture location(s) of a product is dependent upon the
current and perceived financial climate specific to the company including:
o Timing of needed facility (e.g. for phase 3) and projected volumes
o Utilization of internal manufacturing network (current and projected)
o Cash available for pursuing/enabling other options
o Risk profile of the project
* Transport costs and local regulatory environment are not typically significant enough to
be part of the decision process
* Some companies have a global sourcing group in place to facilitate with the location
decision
o The team of decision makers typically includes representatives of:
* President, manufacturing
* VP, API/FG
* Legal
* Tax accountants
* Business development
* The current best thinking is to share risk either with contractors or with governments
acting as a financial partner.
* One manufacturing location decision example in the last decade that included the use of
a new facility was described:
o Product that was not expected to fit in the existing manufacturing network
o Review of potential new sites in Ireland, Puerto Rico, Singapore, and a contract
manufacturer near Montreal
o Rationale for final selection is unclear at this time
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Some key information remains to be determined from ongoing interactions with the industrial
sponsor around the details of:
* How location decisions are/should be made
* Export/repatriation of funds
* Relative amounts of different types of relevant costs
4.2.2 Expectations of the Modeling Efforts
The industrial partner will work with the MIT researchers to investigate:
o Considerations taken (actual and/or ideal) into the decision making process
o Options considered (e.g. outsourcing, new process technologies)
o Specific individuals involved in the decision making process
o Representative cost structures of biomanufacturing facilities
The MIT researchers will investigate:
o Representative probabilistic models for regional volatility
o With inputs of volatility influencers
o The impact of volatility on representative cost structures and asset control
o With outcome of relevance to bottom line as depicted in Figure 12
o Building models with data from the industrial partner
o Incorporating region-specific inputs
o Analyzing resulting models for impact of selected cost structure and asset ownership
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Figure 12. Model framework with inputs creating probabilities of different types of volatility,
each of which impact the bottom line depending on the attenuation caused by the cost
structure and asset ownership structure in place
4.2.3 Enabling the Model Framework
Determining the full details of the model framework depicted in Figure 12 and the associated
analysis of the resulting findings would complete the full intended project. This will require
determining the following with representative sources identified:
* Types and magnitudes of influencers, structures, and events relevant to the region of
interest
o Sources:
* Identified volatility indicators(52; 53)
* Quantifying political change (54)
* Interconnection of institutions and policy volatility (55)
* Empirical relevance of identified volatility indicators(56; 57; 58)
* Resulting probability distributions for the different types of volatility
o Sources:
* Realized distribution of volatility(59; 60)
Reuben Domike MBA Thesis
Political Volatility
Page 48 of 60
* Representative cost structures and asset ownership structures
o Sources:
* Records of publicly traded contract manufacturers
* Direct data from industrial partner
* The attenuation caused by the cost structure and asset ownership structure
o Sources:
* Historical costs from manufacturing as a function of volatility
* Impact of exchange rate volatility on trade and investment(61)
* Quantitative link between political instability and asset ownership
risk(48)
* Regional effects of exchange-rate shocks(62)
In this representative approach, one aspect of the model framework will be demonstrated with
sample data as representative of the expected approach to the full model. The quantitative
attenuation of currency and tax volatility with a sample cost structure is presented in Figure 13
along with associated rationale for the assigned interaction. The sum-product of the relative
fraction of cost and impact yields an attenuation total for each of the two types of volatility for
the specific cost structure shown. In this example, for a 10% change in currency, the bottom
line is altered 8.5% and for a 10% change in tax rate, the bottom line is altered 2.2%. In this
situation, the shape of the volatility distribution is not altered by the cost structure, just simply
attenuated.
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MM MMMi
Product Revenue
Costs of Goods
Rented Real
Assets
Owned Real
Assets
Depreciation
Utilities
Insurance
Interest on Loans
Employee Wages
Employee Benefits
Royalty/License
Local Tax
Attenuation Total
N/A
10%
10%
10%
5%
10%
5%
5%
20%
10%
5%
10%
N/A
50%
100%
Not within region
Goods may be sourced
from elsewhere
Ongoing payments
50% Impact only realized on
sale or valuation
100% Ongoing expense
100% Ongoing expense
100% Ongoing expense
100% Ongoing expense
100% Ongoing expense
100%
0%
100%
85%
Ongoing expense
Likely out of region
Ongoing expense
N/A Not within region
50% Raw materials may be
taxed
10% Property tax may be
relevant
10% Property tax may be
relevant
0% Not influenced
10% Indirect expense
10% Indirect expense
10% Indirect expense
0% Direct wages
unchanged
30% Payroll taxes
0% Likely out of region
100% Direct expense
22% Assumes uniform tax
change
Figure 13. Sample cost structure and quantitative impact of currency and tax changes
Depending upon the firm's appetite for variability in the bottom line, techniques such as
hedging for currency fluctuations could alter the shape of the incoming probability distributions
to offset some of currency volatility risk.
4.3 Specific Research Outcomes
Specifically, results of the data model, interviews, and case studies will quantify answers to the
following questions of importance to manufacturing location decisions:
* What is the relative importance of current determining factors and conditions in
decisions to outsource production of biologics to off-shore locations?
* How have these factors changed over time and how are they expected to change in the
future?
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* How is regional volatility incorporated in these decisions and how should it be?
* How does the relative importance of these factors change over the lifecycle of a product
and the maturity of the company?
* What is the impact of these factors on decision models for biopharmaceutical
companies, North American biocluster efforts to structure incentives, and economic
policy makers related to biologics manufacturing?
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6 Appendix A: Executive Summary of Research Program on Reducing
Costs of Biologics and Vaccines to Remote Locations
Reducing Costs of Packaging and Delivery of Vaccines and Biologics
Improving the Economic Drivers for Global Access to Disease Prevention and Treatment
Summarized by Reuben Domike, Ph.D.
Based on group discussion at BioMAN Futures Meeting in February, 2009
I. Research Motivation and Intent
Challenges arise in economically delivering vaccines and biologics that have cold chain requirements to
remote and/or poor locations. These challenges may include the difficulties in delivering a thermally
sensitive product and/or the lack of a profit motive. The largest supply chain logistics challenge and cost
for many vaccines and biologics is perceived to be one and the same: maintaining the product within its
specified temperature. A recent study concluded that between 14% and 35% of refrigerators or
transport shipments expose vaccines to freezing temperatures,' which is expected to damage many
current and emerging vaccines.2 Some doses are exposed to elevated temperatures in their
transportation, as a recent study of rural Bolivian deliveries demonstrated in finding that seven of the
eleven central deliveries exposed the doses to temperature in excess of 8"C.3 Despite awareness of
these issues and detailed policy guidelines from the World Health Organization,4' 5' 6 millions of vaccine
doses are wasted each year due to a lapse in recommended storage conditions.7
To overcome this challenge and cost, it is the intent of this research to make the cost of distribution and
packaging small relative to the cost of an inexpensive product (e.g. a common vaccine). Specific avenues
of research that will be pursued include thermal stabilization of formulations, multi-dose packaging,
improved cold chain logistics, and active cooling transportation options. Aspects of these have been
pursued elsewhere. It is the intent of this research to provide a comprehensive solution to this challenge
and cost to improve economic drivers of delivering life-saving therapeutics to underserved populations.
II. Coordinated Competencies and Resources
The competencies perceived necessary for providing a comprehensive solution include:
* Stabilization chemistry and engineering
* Product formulation
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* Microsensors of temperature and stability
* Material selection
* Regulatory support for the project
The Center for Biomedical Innovation (CBI) at MIT builds on a history of collaborative excellence at the
interface of academia, industry (including biopharmaceuticals and vendors), and regulators. CBI
believes that MIT and its partners are well positioned with these competencies to coordinate a
comprehensive solution.
CBI specifically anticipates this to be a 3-5 year project starting with approximately 6 FTEs (graduate
students, post-docs, etc.) in the areas of competency listed above, leveling to 10 FTEs in the second
year.
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